Vertex Pharmaceuticals (VRTX) Accumulated Depreciation & Amortization (2009 - 2025)

Vertex Pharmaceuticals has reported Accumulated Depreciation & Amortization for 17 years, with the latest figure at $1.2 billion in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 13.08% year-over-year to $1.2 billion; the trailing twelve-month figure through Dec 2025 stood at $1.2 billion (up 13.08% YoY), and the FY2025 full-year result was $1.2 billion, up 13.08% from the prior year.
• Accumulated Depreciation & Amortization for Q4 2025 stood at $1.2 billion, up from $1.1 billion in the prior quarter.
• The five-year high for Accumulated Depreciation & Amortization was $1.2 billion in Q4 2025, with the low at $896.0 million in Q4 2021.
• Average Accumulated Depreciation & Amortization over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2024.
• Year-over-year, Accumulated Depreciation & Amortization rose 15.73% in 2023 and decreased 10.44% in 2024.
• Tracing VRTX's Accumulated Depreciation & Amortization over 5 years: stood at $896.0 million in 2021, then grew by 14.65% to $1.0 billion in 2022, then climbed by 15.73% to $1.2 billion in 2023, then declined by 10.44% to $1.1 billion in 2024, then climbed by 13.08% to $1.2 billion in 2025.
• The last three Accumulated Depreciation & Amortization figures came in at $1.2 billion (Q4 2025), $1.1 billion (Q4 2024), and $1.2 billion (Q4 2023), per Business Quant data.

Peer Comparison